couter

Si-bone, Inc. sells minimally invasive surgical solutions for spinal procedures, targeting orthopedic surgeons and hospitals. The next catalyst is Nov 3, 2026 — Q3 2026 Earnings Release, which will test the company’s ability to sustain its 20.2% YoY revenue growth and deliver a path to profitability.

  • Revenue grew 20.2% year-over-year to $205.88M, but net income remains negative at -$17.32M.
  • Free cash flow is -$26.08M, and net margin is -8.4%, reflecting ongoing investment in growth.
  • Debt-to-equity is 0.20x, suggesting limited leverage but also limited capacity for capital-intensive expansion.

The Read

SI-BONE's historical moves around key catalysts have averaged about 19.
Nov 2, 2026 — Q3 2026 Earnings Release
Chart by TradingView

The schedule

  • Mon2Nov

    The earnings release will test the company's ability to deliver on its guidance and show progress in its core therapeutic areas, unlike the last report which underperformed on margin compression.

  • Thu12Nov

    The meeting will test the company's ability to demonstrate strategic alignment with industry standards and regulatory expectations, which could influence investor sentiment and long-term growth prospects.

  • Mon23Nov

    The event will test the company's progress in obtaining regulatory approval for new product indications, which is critical for expanding its market reach and revenue potential.

  • Fri15Jan

    The event will test the company's ability to secure favorable reimbursement codes from CMS, which is essential for maintaining profitability and market share in key therapeutic areas.

  • Wed20Jan

    Release of long-term durability data for iFuse-3D and potential expansion of coverage by private payers.

  • Tue9Feb

    The release will test the company's ability to show revenue growth and improved cash flow, which could signal a shift from the last quarter's underperformance on mix.

  • Mon10May

    The release will test the company's ability to show sustained revenue growth and margin expansion, which could signal a shift from the last quarter's underperformance on mix.

  • Tue3Aug

    The release will test the company's ability to show sustained revenue growth and margin expansion, which could signal a shift from the last quarter's underperformance on mix.

  • Tue2Nov

Past

  • Tue4Aug

    Actual outcome: Bull · $18.80 at outcome

    Si-Bone reported a quarterly loss of $0.09 per share, slightly beating the estimate of $0.15, and raised 2026 guidance, showing strong revenue growth and a significant increase in adjusted EBITDA. The positive forward guidance and strategic developments, such as expanded product portfolio and international demand, drove the stock higher despite the EPS miss.

    Q2 2026 earnings assessment focusing on whether SI-BONE can maintain its dramatic Q1 EBITDA improvement.

  • Wed8Jul

    Actual outcome: Bull · $17.25 at outcome

    The stock rose 2.1% following the event as the market focused on SI-BONE's balance sheet and potential for a secondary equity offering. The appointment of Ian Wells as CFO and Tom West to the board signaled enhanced financial leadership and strategic direction, reinforcing investor confidence despite mixed earnings results.

    Market evaluation of SI-BONE's balance sheet and potential for a secondary equity offering given recent price appreciation.

  • Mon11May

    Actual outcome: Bull · $14.84 at outcome

    SI-BONE reported strong Q1 2026 results, delivering 11% worldwide revenue growth and a massive 440% improvement in adjusted EBITDA. The company also raised its full-year 2026 guidance, citing new product launches, expanding physician adoption, and a proposed Medicare reimbursement change. This combination of top-line growth, significant margin expansion, and an upgraded outlook alleviated competitive concerns and drove the stock up nearly 28% to surpass the bull target.

    Q1 2026 results and updated commentary on competitive dynamics in sacroiliac joint fusion and broader MIS spine will be the first test of whether SI-BONE can sustain mid‑teens revenue growth while keeping recent margin gains, with the stock at $13.17 pricing in guidance disappointment after the Q4 2025 selloff.

  • Tue24Feb

    Actual outcome: Mixed · $15.52 at outcome

    SI-BONE reported in-line EPS and highlighted 20% worldwide revenue growth alongside positive adjusted EBITDA and Q4 free cash flow generation. While the initial market reaction was a muted 1.5% gain, the stock subsequently trended downward to breach the $15.00 bear floor by May. This indicates that despite the positive Q4 milestones, the company's 2026 financial guidance failed to sustain investor confidence over the longer term.

    Release of Q4 results and full-year 2026 guidance. Investor focus will be on sustained 20%+ revenue growth and the credible timeline for achieving positive Adjusted EBITDA.